Table 1.
Cohort Characteristics
| Parameter | PXE | Controls |
|---|---|---|
| Number | 20 | 30 |
| Age (years), mean ± SD | 63.4 ± 6.4 | 64.8 ± 11.8 |
| Female | 12 (60%) | 11 (36.7%) |
| Retinal condition | ||
| PXE | 20 | — |
| Diabetic macular edema | — | 13 |
| Central serous retinopathy | — | 7 |
| Central retinal vein occlusion | — | 6 |
| Branch retinal vein occlusion | — | 4 |
| Study anti-VEGF injection | ||
| OD | 12 (60%) | 13 (43.3%) |
| OS | 8 (40%) | 17 (56.7%) |
| Bevacicumab | 14 (70%) | 22 (73.3%) |
| Ranibizumab | 2 (10%) | 1 (3.3%) |
| Aflibercept | 4 (20%) | 5 (16.7%) |
| Faricimab | 0 (0%) | 2 (6.7%) |
| Previous anti-VEGF injections SE, [median; IQR] | 41 [25.5; 56.75] | 11 [5; 28.25] |
| Bevacizumab | 61.5% | 68.9% |
| Ranibizumab | 22.4% | 4.9% |
| Aflibercept | 16.4% | 24.7% |
| Faricimab | 0% | 0.4% |
| Previous transient vision loss | 7 (35%) | 1 (3.3%) |
| Requiring paracentesis | 0 | 0 |
| Requiring topical therapy | 1 | 0 |
| Requiring acetazolamide | 2 | 0 |
| Glaucoma diagnosis | 0 | 5 |
| Previous topical antiglaucomatous therapy | 0 | 7 |
| Axial length SE (mm), mean ± SD | 23.7 ± 1.0 | 23.4 ± 1.1 |
| Angioid streak length (µm), mean ± SD | ||
| SE | 7965.6 ± 2531.3 | 0 |
| FE | 7267.7 ± 2617.0 | 0 |
FE, fellow eye; OD, oculus dexter; OS, oculus sinister; SE, study eye.